BEVC

BEVC is an early-stage venture capital firm founded in 2023 and based in Berkeley, California. It invests in pioneers transforming cutting-edge science into disruptive companies, founded by a collective of scientists, entrepreneurs, and investors driven to advance science for societal benefit. The firm positions itself as the preferred investor for the UCSF and Berkeley research ecosystems, partnering closely with initiatives like Bakar Labs, Bakar Fellows, and UCSF Innovation Ventures to identify technical founders emerging directly from world-class research institutions. BEVC's focus spans health, AI and the future of intelligence, and deep tech, from molecules to materials to energy. The firm invests at the Pre-Seed, Seed, and Series A stages, prioritizing the San Francisco Bay Area, with a portfolio of 8 companies including AIMATX, Addition Therapeutics, Dextera Biosciences, Montara Therapeutics, and PinkDx. The firm's investment approach emphasizes deep technical, strategic, and operational engagement, working hands-on with scientist-founders to convert bold, early-stage research into scalable, defensible businesses.